Michael S. Mathisen

Cancer Drugs in the United States: <i>Justum Pretium</i>—The Just Price

Hagop M. Kantarjian, Tito Fojo, Michael S. Mathisen et al. · Journal of Clinical Oncology · 2013 · 284 citations · Full text

Public Affairs, Health Policy, Pharmaceutical Policy +17

Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial

Solange Peters, Rafał Dziadziuszko, Alessandro Morabito et al. · Nature Medicine · 2022 · 111 citations · Full text

Medicine, Oncology, Pharmacology +17

The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality

Emily Wang, Dimitrios Farmakiotis, Daisy Yang et al. · Journal of Antimicrobial Chemotherapy · 2015 · 81 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16

Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort

Rafał Dziadziuszko, Tony Mok, Solange Peters et al. · Journal of Thoracic Oncology · 2021 · 61 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high‐dose cytarabine‐based induction chemotherapy

Elias Jabbour, Naval Daver, Richard E. Champlin et al. · American Journal of Hematology · 2013 · 55 citations · Full text

Medicine, Oncology, Chemotherapy +15